Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG CLASS:

Beta radiation emitter

DRUG CLASS:

Beta radiation emitter

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Related drugs:

‹

177 Lu-FC705 (0)

OTSA101-DTPA-90Y (0)

177Lu-lilotomab satetraxetan (4)

lutetium Lu 177 vipivotide tetraxetan (4)

ibritumomab tiuxetan (3)

lutetium Lu 177 dotatate (2)

177Lu-DOTA-EB-FAPI (0)

177Lu-DTPA-omburtamab (0)

177Lu-HER3 ARC (0)

177Lu-LNC1003 (0)

177Lu-LNC1004 (0)

177Lu-LNC1010 (0)

177Lu-P17-087 (0)

177Lu-P17-088 (0)

177Lu-PSMA-R2 (0)

90Y-PPMX-T002 (0)

iobenguane I 131 (0)

iodine I 131 tositumomab (0)

Cu-67 SAR-Bombesin (0)

Iodine-131-labeled metuximab (0)

epratuzumab Y-90 (0)

131I-omburtamab (0)

yttrium-90 microspheres (0)

lutetium-177 DOTA satoreotide (0)

67Cu MeCOSar octreotate (0)

177Lu-edotreotide (0)

yttrium 90 microspheres (0)

177 Lu-FC705 (0)

OTSA101-DTPA-90Y (0)

›

CD20 positive	Follicular Lymphoma	CD20 positive	Follicular Lymphoma	rituximab + ibritumomab tiuxetan Sensitive: A1 - Approval rituximab + ibritumomab tiuxetan Sensitive : A1	rituximab + ibritumomab tiuxetan Sensitive: A1 - Approval rituximab + ibritumomab tiuxetan Sensitive : A1
No biomarker	Follicular Lymphoma	No biomarker	Follicular Lymphoma	ibritumomab tiuxetan Sensitive: A1 - Approval ibritumomab tiuxetan Sensitive : A1	ibritumomab tiuxetan Sensitive: A1 - Approval ibritumomab tiuxetan Sensitive : A1
FOLH1 positive	Prostate Cancer	FOLH1 positive	Prostate Cancer	lutetium Lu 177 vipivotide tetraxetan Sensitive: A1 - Approval lutetium Lu 177 vipivotide tetraxetan Sensitive : A1	lutetium Lu 177 vipivotide tetraxetan Sensitive: A1 - Approval lutetium Lu 177 vipivotide tetraxetan Sensitive : A1
SSTR positive	Neuroendocrine Tumor	SSTR positive	Neuroendocrine Tumor	lutetium Lu 177 dotatate Sensitive: A1 - Approval lutetium Lu 177 dotatate Sensitive : A1	lutetium Lu 177 dotatate Sensitive: A1 - Approval lutetium Lu 177 dotatate Sensitive : A1
No biomarker	Marginal Zone Lymphoma	No biomarker	Marginal Zone Lymphoma	ibritumomab tiuxetan Sensitive: A2 - Guideline ibritumomab tiuxetan Sensitive : A2	ibritumomab tiuxetan Sensitive: A2 - Guideline ibritumomab tiuxetan Sensitive : A2
No biomarker	Waldenstrom Macroglobulinemia	No biomarker	Waldenstrom Macroglobulinemia	CLR 131 Sensitive: B - Late Trials CLR 131 Sensitive : B	CLR 131 Sensitive: B - Late Trials CLR 131 Sensitive : B
No biomarker	Lymphoplasmacytic Lymphoma	No biomarker	Lymphoplasmacytic Lymphoma	CLR 131 Sensitive: B - Late Trials CLR 131 Sensitive : B	CLR 131 Sensitive: B - Late Trials CLR 131 Sensitive : B
No biomarker	Prostate Cancer	No biomarker	Prostate Cancer	lutetium Lu 177 vipivotide tetraxetan Sensitive: B - Late Trials lutetium Lu 177 vipivotide tetraxetan Sensitive : B	lutetium Lu 177 vipivotide tetraxetan Sensitive: B - Late Trials lutetium Lu 177 vipivotide tetraxetan Sensitive : B
FOLH1 expression	Prostate Cancer	FOLH1 expression	Prostate Cancer	PNT2002 Sensitive: B - Late Trials PNT2002 Sensitive : B	PNT2002 Sensitive: B - Late Trials PNT2002 Sensitive : B
No biomarker	Prostate Cancer	No biomarker	Prostate Cancer	PNT2002 Sensitive: B - Late Trials PNT2002 Sensitive : B	PNT2002 Sensitive: B - Late Trials PNT2002 Sensitive : B
FOLH1 expression	Prostate Cancer	FOLH1 expression	Prostate Cancer	pembrolizumab + lutetium Lu 177 vipivotide tetraxetan Sensitive: C3 – Early Trials pembrolizumab + lutetium Lu 177 vipivotide tetraxetan Sensitive : C3	pembrolizumab + lutetium Lu 177 vipivotide tetraxetan Sensitive: C3 – Early Trials pembrolizumab + lutetium Lu 177 vipivotide tetraxetan Sensitive : C3
ATM mutation	Prostate Cancer	ATM mutation	Prostate Cancer	enzalutamide + lutetium Lu 177 vipivotide tetraxetan Sensitive: C4 – Case Studies enzalutamide + lutetium Lu 177 vipivotide tetraxetan Sensitive : C4	enzalutamide + lutetium Lu 177 vipivotide tetraxetan Sensitive: C4 – Case Studies enzalutamide + lutetium Lu 177 vipivotide tetraxetan Sensitive : C4